The world has been greatly shaken by the negative effects of the economic crisis, which has let small companies in great need of capital in order to continue their activity.
(prHWY.com) January 9, 2013 - USA, WA -- Socius Capital Group can be regarded as the kind of help the modern economy needs. Since the economic crisis has hit the world of financing in 2008, investments seemed to have entered a rather closed area, with only a few companies facing up to the immediate challenges which appeared. Efficient small companies, from which modern society could have a lot to gain, have found themselves in the difficult situation of a total lack of capital. For this reason, these firms have ceased their activity as well as their researches. Socius Capital Group is a passive investor group, which is designed to offer the help these companies crave for. It is true that there is a lot of competition on the investment market, but what sets Socius Capital Group apart from others is the lack of excessive demands and requirements which other groups make a habit out of asking. Socius Capital Group aims at investing in all gems which the stock market seems to disregard, allowing their activity to continue and reach impressive results.
Involved in domains like technology, medicine, natural resources, media, life sciences, Socius Capital Group has an impressive business portfolio. Pharming Group NV is one of the companies helped by Socius Capital Group, as gross proceeds in value of $ 16,1 million were awarded to the above mentioned company in order for a growth strategy to be developed. Socius Capital Group has made this investment in Pharming Group NV possible having set clear boundaries and at the same time, it has announced that there will be no hedging transaction performed, nor will the stocks be short sold. Another such example is Cell Therapeutics, a biopharmaceutical company which aims at discovering a valid and effective vaccine against cancer, from which Socius Capital Group has bought shares in value of $ 25 million dollars. After putting together all the necessary details, the price per share was established at $ 0.3878 for a period of two years from the issue of the warrant. Cell Therapeutics has decided to use the net proceeds for development and research purposes, as well as for clinical and preclinical testing trials. Moreover, the company is thinking about using the money in purchasing new improved products or technologies, which might speed up the entire process.
Socius Capital Group is not a hedge fund, therefore capital from outside associations or firms will not be accepted. Socius Capital Group was established in 2004 and it is based in Los Angeles and New York. However, this group has invested in companies in Europe, Australia and Asia, not just on the territory of the United States of America. Throughout its activity, Socius Capital Group has carried out successfully 35 different transactions, the investment varying from $ 5 million to $ 50 millions. Carefully investing in health and life sciences domain, this private equity firm has managed to fulfill its purpose, discovering small companies with a high potential and giving them the opportunity to continue their activity. Today, economy is all about investing properly and wisely. Socius Capital Group has managed to find appropriate solutions for many financial difficulties. Visit
http://sociuscapitalnews.wordpress.com to find out more!
###